The resolution introduced on February 27, 2025, designates the first full week in May as Tardive Dyskinesia Awareness Week. It highlights the connection between the use of antipsychotic medications, which are often necessary for managing serious mental illnesses, and the risk of developing tardive dyskinesia (TD), a condition characterized by uncontrollable movements. The resolution emphasizes that many individuals at risk for TD remain undiagnosed, and that early screening and intervention are crucial for improving the quality of life for those affected. It also notes that certain populations, including older adults and individuals with specific mental health conditions, are at a higher risk for developing TD.

Furthermore, the resolution calls for increased awareness and education regarding TD among healthcare providers, patients, and caregivers, advocating for routine screenings as recommended by the American Psychiatric Association. It underscores the importance of early detection and intervention to enhance outcomes for individuals prescribed antipsychotics. The Senate expresses its commitment to raising awareness about TD's causes and symptoms and directs the Clerk of the Senate to send a copy of the resolution to Neurocrine Biosciences to further support these efforts.